LifeMD Inc is a patient-centric, direct-to-patient healthcare company providing a high-quality, cost-effective, and convenient way for patients to access virtual medical care and pharmacy services. The Company's portfolio of brands within continuing operations is now managed as a single operating segment, Telehealth. Telehealth platform integrates core capabilities, includes: A nationwide pharmacy network, A wholly-owned commercial pharmacy, A fully integrated patient care center, A direct-to-patient marketing infrastructure for acquisition and retention, and AI-enabled clinical and operational technologies.
Last trade$1.80
Day change-$0.05 (-2.70%)
Day range$1.73 – $1.86
Volume734,605
Market cap$89M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$89.42M
Price / earnings
—
Price / book
-154.26×
Price / sales
0.6×
EV / sales
0.45×
EV / EBITDA
-2.51×
Profitability
Earnings per share
-$0.07
Return on assets
-5.38%
Return on equity
615.68%
Dividend yield
3.47%
Liquidity and leverage
Debt / equity
-0×
Current ratio
0.8×
Quick ratio
0.63×
Cash ratio
0.36×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$11.21M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for LFMD, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$44.63M
$47.28M
$50.16M
$7.08M
$47.73M
$49.02M
$50.89M
$5.49M
Cost of revenue
$8.25M
$5.28M
$5.93M
$4.23M
$7.06M
$6.84M
$8.14M
$6.8M
Gross profit
$36.38M
$42M
$44.24M
$2.85M
$40.67M
$42.18M
$42.75M
-$1.32M
Selling, general and administrative
$35.51M
$44.29M
$45.05M
$5.01M
$39.15M
$39.82M
$36.61M
-$274.47K
Research and development
$1.88M
$1.79M
$1.8M
-$920.05K
$1.84M
$1.82M
$1.86M
-$244.65K
Total operating expenses
$40.84M
$49.13M
$53.17M
$9.07M
$43.79M
$44.53M
$43.93M
$4.65M
Operating income
-$4.47M
-$7.13M
-$8.93M
-$6.22M
-$3.13M
-$2.35M
-$1.18M
-$5.97M
Interest expense
-$3.21K
$45.66K
$56.48K
$190.79K
-$260.62K
-$660.79K
-$463.64K
-$607.66K
Income before taxes
-$4.47M
-$7.08M
-$8.87M
-$6.03M
-$4.54M
-$3.01M
-$1.65M
-$6.58M
Income taxes
$0
$0
$0
-$123.41K
$31.82K
$0
$0
$365.48K
Net income
-$4.47M
-$7.08M
-$8.87M
$19.94M
-$3.64M
-$1.11M
$348.07K
-$4.63M
Net income attributable to common shareholders
-$5.25M
-$7.86M
-$9.65M
$19.19M
-$4.67M
-$2.4M
-$960.34K
-$5.72M
EBITDA
-$7.52M
-$5.09M
-$6.93M
-$7.39M
-$5.96M
-$561.54K
$509.69K
-$6.72M
Basic earnings per share
-$0.11
-$0.16
-$0.20
$0.41
-$0.10
-$0.05
-$0.02
-$0.14
Diluted earnings per share
-$0.11
-$0.16
-$0.20
$0.41
-$0.10
-$0.05
-$0.02
-$0.14
Recent news
Company coverage with links to the original publishers.
LifeMD announced strategic shifts including direct pharmacy partnerships with Eli Lilly and Novo Nordisk for GLP-1 medications, a major enterprise collaboration with AT&T providing access to 100 million customers, and lower introductory pricing that increased multi-month subscriptions from 25% to 85%. The company expects flat overhead while patient volume grows, positioning it well in the virtual care and pharmacy market.
LifeMD (LFMD) reported a quarterly loss of $0.11 per share, beating consensus estimates of $0.14 loss by 21.43%, but missed revenue expectations with $44.63 million versus the estimated $48.81 million. The company's stock has declined 47.8% year-to-date compared to the S&P 500's 11.3% gain. With a Zacks Rank #3 (Hold) rating, the stock is expected to perform in line with the market.
LifeMD, Inc. (Nasdaq: LFMD) announced a rescheduling of its third quarter 2026 earnings release and conference call from the originally planned date to Thursday, November 12, 2026. The earnings press release is expected at 4:05 p.m. ET, followed by a conference call at 4:30 p.m. ET.
Omada Health (OMDA) reported Q3 2026 earnings of $0.17 per share, beating consensus estimates of $0.09 by 88.89%, with revenues of $91.31 million exceeding expectations by 6.48%. The company has outperformed market estimates four consecutive quarters. However, the stock received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market. Peer company LifeMD is expected to report a quarterly loss of $0.14 per share with declining revenues.
Acadia Healthcare reported Q3 2026 earnings of $0.60 per share, beating consensus estimates of $0.46, with revenues of $895.31 million exceeding expectations by 3%. However, the stock received a Zacks Rank #3 (Hold) rating due to mixed estimate revisions. The Medical-Hospital industry ranks in the bottom 7% of Zacks industries, which could limit future stock performance despite the company's strong year-to-date gains of 108.7%.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.